Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725881 · ClinicalTrials.gov registry record · Phase 1
Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication
A Phase 1 study, sponsored by Diffusion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00725881 is a Phase 1 study that has completed, run by Diffusion Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT00725881, a Phase 1 study, has completed, sponsored by Diffusion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of multiple, once-daily, intravenous doses of trans sodium crocetinate (TSC). The effectiveness of TSC in alleviating the symptoms of intermittent claudication (IC) will also be assessed.
Interventions
- DRUG Trans sodium crocetinate (TSC)
- DRUG 0.9% normal saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00725881
The ClinicalTrials.gov registry entry for NCT00725881 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diffusion Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trans sodium crocetinate (TSC) is the first listed.
NCT00725881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00725881 about?
NCT00725881 is a clinical study titled "Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication". The purpose of this study is to evaluate the safety and pharmacokinetics of multiple, once-daily, intravenous doses of trans sodium crocetinate (TSC). The effectiveness of TSC in alleviating the symptoms of intermittent claudication (IC) will also be assessed.
What is the current status of trial NCT00725881?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2008-08. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00725881?
The interventions under investigation include: Trans sodium crocetinate (TSC) (DRUG), 0.9% normal saline (DRUG).
Who is sponsoring clinical trial NCT00725881?
This trial is sponsored by Diffusion Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.